D. E. Shaw & Co. Inc. Sells 2,664,620 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

D. E. Shaw & Co. Inc. reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 37.6% during the 1st quarter, HoldingsChannel reports. The fund owned 4,414,976 shares of the biopharmaceutical company’s stock after selling 2,664,620 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Amicus Therapeutics were worth $43,620,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of FOLD. First Trust Advisors LP bought a new stake in Amicus Therapeutics in the 1st quarter valued at $635,000. The Manufacturers Life Insurance Company lifted its position in Amicus Therapeutics by 4.3% in the 4th quarter. The Manufacturers Life Insurance Company now owns 153,292 shares of the biopharmaceutical company’s stock valued at $3,540,000 after acquiring an additional 6,319 shares in the last quarter. Federated Hermes Inc. lifted its position in Amicus Therapeutics by 166.7% in the 4th quarter. Federated Hermes Inc. now owns 388,812 shares of the biopharmaceutical company’s stock valued at $8,978,000 after acquiring an additional 243,047 shares in the last quarter. Allstate Corp bought a new stake in Amicus Therapeutics in the 4th quarter valued at $355,000. Finally, American International Group Inc. lifted its position in Amicus Therapeutics by 4.2% in the 4th quarter. American International Group Inc. now owns 158,505 shares of the biopharmaceutical company’s stock valued at $3,660,000 after acquiring an additional 6,461 shares in the last quarter.

Several equities research analysts have issued reports on the stock. Cantor Fitzgerald upgraded shares of Amicus Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Monday, April 19th. Chardan Capital reiterated a “neutral” rating on shares of Amicus Therapeutics in a research note on Thursday, July 1st. Berenberg Bank assumed coverage on shares of Amicus Therapeutics in a research note on Thursday, July 1st. They issued a “hold” rating and a $14.00 price target on the stock. SVB Leerink reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, June 10th. Finally, UBS Group assumed coverage on shares of Amicus Therapeutics in a research note on Thursday, May 20th. They issued a “buy” rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $19.54.

In other news, Director Margaret G. Mcglynn sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, May 3rd. The shares were sold at an average price of $10.27, for a total transaction of $102,700.00. Following the completion of the sale, the director now owns 37,919 shares of the company’s stock, valued at approximately $389,428.13. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO John F. Crowley sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, May 3rd. The stock was sold at an average price of $10.28, for a total transaction of $77,100.00. Following the sale, the chief executive officer now directly owns 884,730 shares of the company’s stock, valued at approximately $9,095,024.40. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 31,605 shares of company stock valued at $278,268 and have sold 104,913 shares valued at $1,052,618. Insiders own 2.50% of the company’s stock.

Shares of FOLD stock opened at $9.16 on Thursday. The company has a market cap of $2.44 billion, a P/E ratio of -9.44 and a beta of 1.12. The company has a quick ratio of 4.86, a current ratio of 5.05 and a debt-to-equity ratio of 1.55. The business’s 50-day moving average is $9.62. Amicus Therapeutics, Inc. has a 52 week low of $8.68 and a 52 week high of $25.39.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Sunday, May 9th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The company had revenue of $66.40 million for the quarter, compared to the consensus estimate of $71.76 million. Amicus Therapeutics had a negative return on equity of 80.85% and a negative net margin of 95.05%. As a group, equities research analysts anticipate that Amicus Therapeutics, Inc. will post -0.81 earnings per share for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates.

Read More: Put Option Volume

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.